Clinical Evaluation of Tibric Acid in Patients with Hyperlipidemia.
10.4070/kcj.1976.6.2.17
- Author:
Rin CHANG
;
Se Hwa YOO
;
Young Bae PARK
;
Jungdon SEO
;
Young Woo LEE
;
Sung Ho LEE
- Publication Type:Original Article
- MeSH:
Anorexia;
Benzoic Acid;
Cholesterol;
Dyspepsia;
Humans;
Hyperlipidemias*;
Hyperlipoproteinemia Type IV;
Triglycerides
- From:Korean Circulation Journal
1976;6(2):17-23
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Tibric acid is a new oral hypolipidemic agent with the chemical name of 2-chloro-5(3,5-dimethyl piperidinosulfonyl) benzoic acid. The results of tibric acid administration in 22 patients with primary hyperlipidemia were as follows. 1) Serum triglyceride level was significantly decreased in 84.6% of 22 cases with an average 43.9% decrease in serum triglyceride. 2) Serum cholesterol level was decreased in 59.1% of 22 cases with an average 15.8% decrease in serum cholesterol. The decrease in serum cholesterol level was not significant. 3) It seemed that there were significant falls in the serum triglyceride of the hyperlipoproteinemia type IV and IIb patietns and in the serum cholesterol of type IIa patients 4) The side effects of tibric acid were indigestion, loose stool and anorexia. There was no side effects in 63.6% of cases.